Journal of Hepatology
Volume 53, Issue 4 , Pages 677-685, October 2010

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

  • Gerben J. van der Bij

      Affiliations

    • Department of Surgical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • ,
  • Marijn Bögels

      Affiliations

    • Department of Surgical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • ,
  • Marielle A. Otten

      Affiliations

    • Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands
  • ,
  • Steven J. Oosterling

      Affiliations

    • Department of Surgical Oncology, VU University Medical Center, Amsterdam, The Netherlands
  • ,
  • Peter J. Kuppen

      Affiliations

    • Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
  • ,
  • Sybren Meijer

      Affiliations

    • Department of Surgical Oncology, VU University Medical Center, Amsterdam, The Netherlands
  • ,
  • Robert H.J. Beelen

      Affiliations

    • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
  • ,
  • Marjolein van Egmond

      Affiliations

    • Department of Surgical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    • Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Address: Department of Molecular Cell Biology and Immunology, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands. Tel.: +31 20 4448079; fax: +31 20 4448081.

published online 25 June 2010.

Background & Aims

Development of liver metastases is a frequent complication in patients with colorectal cancer (CRC), even after successful resection of the primary tumor. As such, post-operative adjuvant therapies that aim to eliminate residual disease after surgery may improve patient outcome.

Methods

We used a colon carcinoma liver metastases model, in which CC531s colon carcinoma cells are injected into the portal circulation by a surgical procedure. As injected tumor cells are arrested in the liver, this model is suitable for investigating the interaction of tumor cells with the liver microenvironment. By administering tumor specific monoclonal antibodies (mAb) directly post-operatively, we were able to determine the effect of antibody therapy on eradication of arrested tumor cells and subsequent liver metastases outgrowth.

Results

We showed that post-operative treatment with tumor specific monoclonal antibodies (mAb) prevents liver metastases outgrowth. Antibody-dependent phagocytosis (ADPh) was the main mechanism involved, as enhanced uptake of tumor cells by innate mononuclear phagocytes in the liver was observed after mAb therapy. Furthermore, Kupffer cells (KC) were identified as the most prominent effector cells, as depletion of KC abolished therapeutic efficacy. This was partly compensated by monocytes when animals were treated with a high mAb dose, but monocytes were unable to phagocytose tumor cells when rats were treated with low mAb doses.

Conclusions

The finding that KC and monocytes can eliminate tumor cells through ADPh has important and promising clinical implications for designing new adjuvant therapies for patients undergoing CRC resection.

Abbreviations: ADCC, antibody dependent cellular cytotoxicity, ADPh, antibody dependent phagocytosis, CRC, colorectal cancer, FcγR, Fc gamma receptor, FCS, fetal calf serum, Ig, immunoglobulin, i.p., intraperitoneal, KC, Kupffer cell, mAb, monoclonal antibody, NK, natural killer

Keywords: Colorectal cancer, Metastasis, Phagocytosis, Kupffer cell, Macrophage, Antibody therapy, ADCC, Surgery

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0168-8278(10)00539-8

doi:10.1016/j.jhep.2010.04.023

Refers to article:

  • Exploiting liver immunity for the prevention of hepatic metastases , 21 June 2010

    Licia Rivoltini, Vincenzo Mazzaferro
    Journal of Hepatology October 2010 (Vol. 53, Issue 4, Pages 596-598)

Journal of Hepatology
Volume 53, Issue 4 , Pages 677-685, October 2010